We have found that chemotherapy and radiation converts the tumor site into an antigen-presenting cell-rich environment, rendering it ideal for the direct injection of a peptide or protein vaccine into the tumor to elicit potent antigen-specific T cell-mediated immune responses. Here, we propose the use of a therapeutic HPV protein vaccine, administered intratumorally, during chemoradiation in patients with inoperable HPV16+ cervical cancer. We have secured the therapeutic HPV protein vaccine TA-CIN from Cancer Research Technology, Ltd. and the adjuvant GPI-0100 from Hawaii Biotech. We have also secured support from the NCI NExT program to formulate and vial clinical grade TA-CIN with GPI-0100. The proposed trial will be performed at the University of Alabama at Birmingham. Specifically we plan to: 1) evaluate the safety and toxicity of TA-CIN with GPI-0100 administered intratumorally in inoperable HPV16+ cervical cancer patients;2) characterize the HPV-16 E6 and E7 cell-mediated immune responses and L2-specific antibody titers in advanced cervical cancer patients intratumorally vaccinated with TA-CIN/GPI-0100;3) determine the subset population of immune cells infiltrating the lesion bed, the expression of PD-L1 in the tumor microenvironment and the apoptotic tumor cell death in HPV 16+ advanced cervical cancer patients receiving intratumoral TA-CIN/ GPI-0100 vaccination;and 4) characterize the HPV-16 antigen-specific CD8+ T cell-mediated immune responses and therapeutic antitumor effects against E6/E7-expressing tumors in tumor-bearing mice treated with intratumoral vaccination with TA-CIN/GPI-0100, TA-HPV vaccinia or pNGVL4a-hCRTE6E7L2 DNA vaccine in conjunction with cisplatin and/or radiation treatment. The successful implementation of the proposed project will not only improve the treatment of HPV-associated advanced cervical cancer but may also serve as a platform technology for the development of effective therapeutic vaccines for other HPV associated malignancies including vaginal, vulva, anal, penile and HPV positive oropharyngeal squamous cell carcinoma.

Public Health Relevance

This project aims to take advantage of the temporally permissive tumor microenvironment induced by chemoradiation and the availability of clinical grade HPV protein-based vaccine to potentially enhance E6/E7 antigen-specific immune responses and antitumor effects in TA-CIN/GPI-0100 vaccinated inoperable HPV- 16+ cervical cancer patients, a population needing new therapeutic paradigms to improve clinical outcomes.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
United States
Zip Code
Yang, Andrew; Farmer, Emily; Lin, John et al. (2016) The current state of therapeutic and T cell-based vaccines against human papillomaviruses. Virus Res :
Yang, Andrew; Farmer, Emily; Wu, T C et al. (2016) Perspectives for therapeutic HPV vaccine development. J Biomed Sci 23:75
Khan, Michelle J; Massad, L Stewart; Kinney, Walter et al. (2016) A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results. Gynecol Oncol 141:364-70
Khan, Michelle J; Massad, L Stewart; Kinney, Walter et al. (2016) A Common Clinical Dilemma: Management of Abnormal Vaginal Cytology and Human Papillomavirus Test Results. J Low Genit Tract Dis 20:119-25
Jiang, Rosie T; Schellenbacher, Christina; Chackerian, Bryce et al. (2016) Progress and prospects for L2-based human papillomavirus vaccines. Expert Rev Vaccines 15:853-62
Wang, Yi-Shu; Chen, Jianfeng; Cui, Fengmei et al. (2016) LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors. Oncotarget :
Sun, Yun-Yan; Peng, Shiwen; Han, Liping et al. (2016) Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract. Clin Cancer Res 22:657-69
Jones, Jacqueline; Mukherjee, Angana; Karanam, Balasubramanyam et al. (2016) African Americans with pancreatic ductal adenocarcinoma exhibit gender differences in Kaiso expression. Cancer Lett 380:513-22
Randles, Leah; Anchoori, Ravi K; Roden, Richard B S et al. (2016) The Proteasome Ubiquitin Receptor hRpn13 and Its Interacting Deubiquitinating Enzyme Uch37 Are Required for Proper Cell Cycle Progression. J Biol Chem 291:8773-83
Yang, Andrew; Jeang, Jessica; Cheng, Kevin et al. (2016) Current state in the development of candidate therapeutic HPV vaccines. Expert Rev Vaccines 15:989-1007

Showing the most recent 10 out of 251 publications